GAM
SLNO

Griffin Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Griffin Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-733
Closed -$21K – 243
2020
Q4 		$21K Hold
733
– – ﹤0.01% 224
2020
Q3 		$28K Buy
+733
New +$21.4K ﹤0.01% 202

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Griffin Asset Management's SLNO Position: Q1 2021 in Review

Griffin Asset Management sold out of Soleno Therapeutics (SLNO) in Q1 2021, closing a stake of 733 shares — an estimated $21K sold.

Griffin Asset Management first reported a position in SLNO in Q3 2020 and held it in 2 quarters. The position peaked at $28K in Q3 2020. 63 funds tracked by Wall St. Rank hold SLNO as of Q1 2021.

  • Griffin Asset Management reported no remaining Soleno Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Griffin Asset Management sold 733 Soleno Therapeutics shares in Q1 2021, an estimated $21K.
  • Griffin Asset Management first reported a position in Soleno Therapeutics in Q3 2020 and held it in 2 quarters.
  • Griffin Asset Management's Soleno Therapeutics position peaked at $28K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2021.

Based on Griffin Asset Management's 13F filing for Q1 2021, filed 4 May 2021.